CLBS119
CLBS119 Uses, Dosage, Side Effects, Food Interaction and all others data.
CLBS119, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
| Trade Name | CLBS119 |
| Generic | Autologous peripheral blood-derived CD34+ cells |
| Autologous peripheral blood-derived CD34+ cells Other Names | CD34+ Cells, CLBS119 |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How CLBS119 works
CLBS119 have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation. Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.
Innovators Monograph
You find simplified version here CLBS119
